Mersana Therapeutics, Inc. (0M4)
XSTU 
Summary
Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $1.51 per share versus the Zacks Consensus Estimate of a loss of $1.44. This compares to a loss of $2.25 per share a year ago.
Mersana Therapeutics, Inc. (MRSN) M&A Call Transcript
Mersana Therapeutics, Inc. ( MRSN ) M&A Call November 13, 2025 8:00 AM EST Company Participants Joey Perrone - Senior Vice President of Finance & Investor Relations Jeremy Bender - CEO, President & Director Michael Vasconcelles - Head of Research & Development Charles York - COO & CFO Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Alec Stranahan - BofA Securities, Research Division Kelsey Goodwin - Piper Sandler & Co., Research Division Ami Fadia - Needham & Company, LLC, Research Division Presentation Operator Hello, ladies and gentlemen, and welcome to the conference call and live webcast Day One Biopharmaceuticals to acquire Mersana Therapeutics. [Operator Instructions] Please be advised that this conference call is being recorded.
Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Brian C. DeSchuytner - Senior VP, CFO & COO Jason Fredette - Senior Vice President of Investor Relations & Corporate Communications Martin H.
Mersana Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Martin H. Huber CEO | XSTU Exchange | US59045L1061 ISIN |
| US Country | 102 Employees | - Last Dividend | 28 Jul 2025 Last Split | 28 Jun 2017 IPO Date |
Overview
Mersana Therapeutics, Inc. is a pioneering clinical stage biopharmaceutical company, concentrated on the development of innovative antibody drug conjugates (ADCs) designed to meet the unmet needs of cancer patients. Leveraging its proprietary platforms and scientific expertise, the company focuses on creating therapies that can potentially transform cancer treatment. Initially founded as Nanopharma Corp. in 2001, Mersana rebranded to its current name in November 2005 and has since established its headquarters in Cambridge, Massachusetts. The organization champions a collaborative approach, holding research and development partnerships with notable entities such as Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC, aiming to broaden and enhance its ADC product candidates' portfolio.
Products and Services
Mersana Therapeutics, Inc. is dedicated to advancing the treatment of cancer through its diverse pipeline of ADC candidates. Each is designed with a targeted approach to attack tumor cells while sparing healthy tissues, which could offer a more effective and safer treatment option for patients.
- XMT-1660
- XMT-2056
This innovative product candidate operates as a B7-H4-targeted Dolasynthen ADC, aiming to provide a novel therapy option for patients struggling with various forms of cancer. The targeting mechanism of XMT-1660 focuses on B7-H4, a protein often overexpressed in multiple tumor types, providing a strategic method to deliver therapeutic agents directly to cancer cells.
As another element of Mersana's ADC pipeline, XMT-2056 is developed under the ImmunSynthen platform. This therapy is designed not only to target and eradicate cancer cells but also to stimulate an immune response against the tumor. XMT-2056 represents a cutting-edge approach in oncology, potentially integrating targeted therapy with immunotherapy to enhance treatment effectiveness.
Contact Information
